Caribou Biosciences has a performance score of 9 on a scale of 0 to 100. The company has a Beta (market volatility) of 0.1179, indicating relatively insignificant fluctuations compared to the market. To interpret Caribou's beta, as market returns increase, Caribou Biosciences' returns are expected to rise less than the market. Conversely, during a bear market, losses from holding Caribou Biosciences are anticipated to be smaller.
While it's crucial to consider Caribou Biosciences' historical returns, one should be cautious when using this information to predict current equity trends. The approach to forecasting the future performance of any stock involves a comprehensive evaluation of the business, its past performance, and all available fundamental and technical indicators.
For Caribou Biosciences, we have identified twenty-one technical indicators that can be used to assess the company's performance. Please utilize Caribou Biosciences' standard deviation, maximum drawdown, and the relationship between the maximum drawdown and expected shortfall to make a swift decision on whether Caribou Biosciences' price patterns will revert.
Deep-dive analysis
Investors considering Caribou Biosciences (CRBU) should take note of the company's recent performance and financial indicators. Despite reporting a net income loss of
99.4M and a negative return on assets of 0.18, the company's stock has been on a bullish run, reaching a 52-week high of 13.19. The company's total revenue stands at
13.9M, and it has a short percent of 0.1325, indicating that a significant portion of its shares are being shorted. However, the company's risk-adjusted performance is positive at 0.0698, suggesting that it may continue to provide returns that outweigh the risks. Investors should weigh these factors carefully when considering an investment in CRBU.
What is the right price you would pay to acquire a share of Caribou Biosciences? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
What is happening with Caribou Biosciences this year
Annual and quarterly reports issued by Caribou Biosciences are formal
financial statements that are published yearly and quarterly and sent to Caribou stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Caribou Biosciences often view their annual report as an effective marketing tool to disseminate their perspective on company
future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Caribou Biosciences Gross Profit
Caribou Biosciences Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Caribou Biosciences previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Caribou Biosciences Gross Profit growth over the last 10 years. Please check Caribou Biosciences'
gross profit and other
fundamental indicators for more details.
Is Caribou a risky opportunity?
Let's check the volatility. Caribou is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Caribou (USA Stocks:CRBU) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. acquiring a share of a Caribou Biosciences stock makes you a part-owner of that company.
Caribou Biosciences Current Consensus
Here is the newest trade recommendation based on an ongoing consensus estimate among financial analysis covering Caribou Biosciences. The Caribou consensus assessment is calculated by taking the average estimates from all of the analysts covering Caribou Biosciences
| Strong Buy | 5 | 83.33 |
| Buy | 1 | 16.67 |
| Hold | 0 | 0.0 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
Caribou Biosciences (CRBU), a clinical-stage biopharmaceutical company, has been enjoying a bullish run in the stock market, prompting analysts to weigh in on its
future performance. The company, which operates in the Biotechnology industry, has a market capitalization of
$479.55 million and a total of 66.05 million shares outstanding. The company's stock has a 52-week high of $13.19 and a 52-week low of $3.96, with a current ratio of 12.23X indicating a healthy financial position. Despite an operating income loss of $106.4 million and a net income loss of $99.4 million, the company has a strong net asset position of $373.76 million and a manageable total debt of $27.75 million. The company's price to book ratio stands at 1.54X, which is relatively low compared to the industry average, suggesting that the stock may be undervalued. The company's shares are largely owned by institutions, with a significant 73.20% stake, while insiders own 10.83%. There are currently 7.58 million shares shorted, representing 0.1325% of the total shares. However, with a target price of $27.5 and a potential upside of 10.14%, the bullish run may continue. The company's strong cash position, with cash per share at 5.59X, and a healthy working capital of
$232.12 million, further supports this outlook. Despite the bullish trend, investors should be aware of the company's high probability of bankruptcy at 27.30%. The final decision should be based on individual risk tolerance and investment objectives.
Are Caribou Biosciences technical ratios showing a relapse?
The latest standard deviation of 7.68 for Caribou Biosciences serves as an indicator of the stock's volatility, potentially signaling a downturn in the company's technical ratios. A higher standard deviation suggests a broader dispersion of returns, indicating a higher level of risk and potential instability. Investors should proceed with caution and closely monitor the stock's performance, as this could indicate a turbulent period for Caribou Biosciences. It's essential to consider this risk when making investment decisions in the near term. Caribou Biosciences has shown above-average volatility over the selected time horizon. Investors should carefully analyze Caribou Biosciences to ensure that their intended
market timing strategies align with their expectations about the company's volatility. Understanding different
market volatility trends can often assist investors in timing the market. Proper use of volatility indicators allows traders to gauge the risk of Caribou Biosciences' stock against market volatility during both bullish and bearish trends.
The heightened level of volatility that accompanies bear markets can directly affect
Caribou Biosciences' stock price, adding stress for investors as they watch the value of their shares decline. This typically prompts investors to rebalance their portfolios by purchasing different stocks as prices drop. In light of today's market performance, Caribou Biosciences has demonstrated a commendable uptick despite a modest market drop. The company, a clinical-stage biopharmaceutical firm with a focus on genome-edited allogeneic cell therapies, has a valuation market value of
7.26 and a valuation real value of
12.17. Analysts have a strong consensus towards a 'Buy' rating, with 5 strong buys and 1 buy, out of a total of 6 estimates. The possible upside price is pegged at 14.63, while the downside risk is relatively low at 0.0726. The target price estimated value stands at a promising 28, with the highest estimated target price reaching up to 38. Given these data points, investing in Caribou Biosciences stock could offer substantial returns for investors willing to navigate the inherent risks of the biopharmaceutical sector. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Caribou Biosciences. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
